Abstract
Neoadjuvant chemotherapy (NACT) is known to be beneficial for patients with locally advanced breast cancer. However, there is still no unified standard on the evaluation of NACT. To identify the potential markers related to NACT sensitivity of breast cancer, in the present study, we examined the protein spectrum of breast cancer tissues before and after NACT using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS). Totally, 87 protein samples were extracted from tissues of breast cancer, with 30 from patients before NACT, 30 from patients after NACT, and 27 from patients without any treatment. To eliminate confounding factors a couple of tissue samples from the same patient were mixed. SELDI-TOF MS analysis demonstrated that the intensities of eight different protein peaks, i.e., 26,055.46, 17,898.94, 8,949.50, 11,652.02, 11,053.48, 38,546.56, 5,825.89, and 22,250.63 Da, were higher in samples after NACT than those before NACT. Although further experiments are needed to prove the reliability of the proteins identified in this study, our results will help the establishment of protein model based on drug resistance-related protein peaks to screen whether a patient is suitable for adopting NACT and to improve cancer treatment.
Similar content being viewed by others
References
Akhsan, A., & Aryandono, T. (2010). Asian Pacific Journal of Cancer Prevention, 11, 759–761.
Khokher, S., Mahmood, S., & Khan, S. A. (2010). Asian Pacific Journal of Cancer Prevention, 11, 303–308.
Garces, C. A., & Cance, W. G. (2004). The American Surgeon, 70, 565–569.
Choi, J. H., Lim, H. I., Lee, S. K., Kim, W. W., Kim, S. M., Cho, E., et al. (2010). Journal of Surgical Oncology, 102, 392–397.
Straver, M. E., Aukema, T. S., Olmos, R. A., Rutgers, E. J., Gilhuijs, K. G., Schot, M. E., et al. (2010). European Journal of Nuclear Medicine and Molecular Imaging, 37, 1069–1076.
Keune, J. D., Jeffe, D. B., Schootman, M., Hoffman, A., Gillanders, W. E., & Aft, R. L. (2010). American Journal of Surgery, 199, 477–484.
Masuda, H., Masuda, N., Kodama, Y., Ogawa, M., Karita, M., Yamamura, J., et al. (2011). Cancer Chemotherapy and Pharmacology, 67, 911–917.
Tewari, M., Pradhan, S., Singh, U., Singh, T. B., & Shukla, H. S. (2010). Asian Journal of Surgery, 33, 157–167.
Ricolleau, G., Charbonnel, C., Lode, L., Loussouarn, D., Joalland, M. P., Bogumil, R., et al. (2006). Proteomics, 6, 1963–1975.
Ushijima, M., Miyata, S., Eguchi, S., Kawakita, M., Yoshimoto, M., Iwase, T., et al. (2007). Cancer Information, 3, 285–293.
Gast, M. C., van Dulken, E. J., van Loenen, T. K., Kingma-Vegter, F., Westerga, J., Flohil, C. C., et al. (2009). The International Journal of Biological Markers, 24, 130–141.
Gast, M. C., Van Gils, C. H., Wessels, L. F., Harris, N., Bonfrer, J. M., Rutgers, E. J., et al. (2009). Oncology Reports, 22, 205–213.
Gast, M. C., van Gils, C. H., Wessels, L. F., Harris, N., Bonfrer, J. M., Rutgers, E. J., et al. (2009). Clinical Chemistry and Laboratory Medicine, 47, 694–705.
Gast, M. C., Schellens, J. H., & Beijnen, J. H. (2009). Breast Cancer Research and Treatment, 116, 17–29.
Gast, M. C., Engwegen, J. Y., Schellens, J. H., & Beijnen, J. H. (2008). BMC Medical Genomics, 1, 4.
Lu, H. B., Zhou, J. H., Ma, Y. Y., Lu, H. L., Tang, Y. L., Zhang, Q. Y., et al. (2010). Japanese Journal of Clinical Oncology, 40, 336–342.
Fan, Y., Wang, J., Yang, Y., Liu, Q., Yu, J., Zheng, S., et al. (2010). Journal of Cancer Research and Clinical Oncology, 136, 1243–1254.
Solassol, J., Rouanet, P., Lamy, P. J., Allal, C., Favre, G., Maudelonde, T., et al. (2010). Oncogene, 29, 550–560.
Wang, X., Dai, S., Zhang, Z., Liu, L., Wang, J., Xiao, X., et al. (2009). European Journal of Cancer Care, 18, 625–635.
Apweiler, R., Martin, M. J., O’Donovan, C., Magrane, M., Alam-Faruque, Y., Antunes, R., et al. (2010). Nucleic Acids Research, 38, D142–D148.
Li, J., Zhang, Z., Rosenzweig, J., Wang, Y. Y., & Chan, D. W. (2002). Clinical Chemistry, 48, 1296–1304.
Li, J., Orlandi, R., White, C. N., Rosenzweig, J., Zhao, J., Seregni, E., et al. (2005). Clinical Chemistry, 51, 2229–2235.
Pusztai, L., Gregory, B. W., Baggerly, K. A., Peng, B., Koomen, J., Kuerer, H. M., et al. (2004). Cancer, 100, 1814–1822.
Pietrowska, M., Polanska, J., Marczak, L., Behrendt, K., Nowicka, E., Stobiecki, M., et al. (2010). Journal of Translational Medicine, 8, 66.
van Winden, A. W., Gast, M. C., Beijnen, J. H., Rutgers, E. J., Grobbee, D. E., Peeters, P. H., et al. (2009). BMC Medical Genomics, 2, 4.
Li, Y., Wen, Z., Xiao, J., Yin, H., Yu, L., Yang, L., et al. (2011). BMC Bioinformatics, 12, 14.
Deng, X., Geng, H., Bastola, D. R., & Ali, H. H. (2006). Computational Biology and Chemistry, 30, 425–433.
Chen, W. C., Lai, C. C., Tsai, Y., Lin, W. Y., & Tsai, F. J. (2008). Journal of Clinical Laboratory Analysis, 22, 77–85.
Acknowledgements
This study was supported by Provincial Natural Science Foundation of Shandong Province, China (No.Y2008C15).
Author information
Authors and Affiliations
Corresponding author
Additional information
Zhang and Yuan contribute equally to this article.
Rights and permissions
About this article
Cite this article
Zhang, K., Yuan, K., Wu, H. et al. Identification of Potential Markers Related to Neoadjuvant Chemotherapy Sensitivity of Breast Cancer by SELDI-TOF MS. Appl Biochem Biotechnol 166, 753–763 (2012). https://doi.org/10.1007/s12010-011-9464-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12010-011-9464-z